clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2020-98-11-12-745-751clinmed-156Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESМедикаментозные токсидермии: возможные причины, клинические проявления и подходы к ведению пациентов на догоспитальном этапеDrug toxicoderma: possible causes, clinical manifestations and approaches to management at the outpatient’s stagehttps://orcid.org/0000-0001-7825-5597ЛаринаВ. Н.LarinaV. N.

Ларина Вера Николаевна — доктор медицинских наук, зав. кафедрой поликлинической терапии лечебного факультета

117997, Москва

Vera N. Larina — MD, PhD, DSc, Head of the Department of Polyclinic Therapy of the Faculty of Medicine

117997, Moscow

https://orcid.org/0000-0001-8485-3294ГайдинаТ. А.GaydinaT. A.

117997, Москва

117997, Moscow

https://orcid.org/0000-0002-0429-3117ДворниковА. С.DvornikovA. S.

117997, Москва

117997, Moscow

https://orcid.org/0000-0001-5343-4847НазимкинК. Е.NazimkinK. E.

117997, Москва

117997, Moscow

ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава РоссииРоссияPirogov Russian National Research Medical University of the Ministry of Health of RussiaRussian Federation2020170420219811-12745751Copyright © Ларина В.Н., Гайдина Т.А., Дворников А.С., Назимкин К.Е., 20212021Ларина В.Н., Гайдина Т.А., Дворников А.С., Назимкин К.Е.Larina V.N., Gaydina T.A., Dvornikov A.S., Nazimkin K.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/156

Ежегодно у многих людей в мире развиваются нежелательные кожные реакции (НКР) в ответ на прием лекарственных препаратов (ЛП). Медикаментозные токсидермии (МТ) являются наиболее распространенными НКР и трудно диагностируемыми на ранних стадиях. Разработка и активное внедрение в практику новых ЛП, бесконтрольное самолечение пациентов, полипрагмазия, повторные курсы одними и теми же ЛП способствуют росту МТ. Врачам необходимо проявлять повышенное внимание к пациентам с МТ, которые могут развиться в любой период времени после приема ЛП и иметь разные клинические проявления. Механизмы развития МТ изучены не окончательно, что ограничивает возможность их диагностики, лечения и профилактики. Оценка соотношения польза/риск при выборе ЛП является основой фармакобезопасности и должна в обязательном порядке проводиться врачами всех специальностей, в первую очередь врачами первичного звена здравоохранения.

Adverse cutaneous drug reactions are skin manifestations resulting from systemic drug administration. Toxicoderma under medication treatment is the most common adverse cutaneous reaction with difficulty to diagnose, especially at early stages. The development and active introduction of new drugs into practice, uncontrolled self-medication of patients, polypharmacy, and repeated contact with one and the same preparation, contribute to the growth of toxicoderma. Doctors should treat patients with toxicoderma carefully, as it can be developed at any time and have different clinical manifestations. The pathogenesis of toxicoderma is not fully understood, which limits the possibility of the diagnosis, treatment and prevention. The benefit/risk ratio evaluation of prescribing medications is the basis of pharmacological safety and doctors, especially of primary health care (general practitioners), should always put it into practice.

медикаментозная токсидермиякожные нежелательные реакциисиндром Стивенса– Джонсонасиндром Лайеллафармакобезопасностьtoxicodermacutaneous adverse drug reactionsStevens–Johnson syndromeLyell`s syndromepharmaco-logical safetyReferencesFormica D., Sultana J., Cutroneo P.M., Lucchesi S., Angelica R., Crisafulli S., Ingrasciotta Y., Salvo F., Spina E., Trifirò G. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opin. Drug. Saf. 2018;17(7):681–695. DOI: 10.1080/14740338.2018.1491547Formica D., Sultana J., Cutroneo P.M., Lucchesi S., Angelica R., Crisafulli S., Ingrasciotta Y., Salvo F., Spina E., Trifirò G. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opin. Drug. Saf. 2018;17(7):681–695. DOI: 10.1080/14740338.2018.1491547Aung A., Tang M., Adler N., de Menezes S.L., Goh M.S.Y., Tee H.W., Trubiano J.A., Puy R., Zubrinich C.M., Graudins L.V. Adverse Drug Reactions Reported by Healthcare Professionals: Reaction Characteristics and Time to Reporting. J. Clin. Pharmacol. 2018;58(10):1332–1339. DOI: 10.1002/jcph.1148Aung A., Tang M., Adler N., de Menezes S.L., Goh M.S.Y., Tee H.W., Trubiano J.A., Puy R., Zubrinich C.M., Graudins L.V. Adverse Drug Reactions Reported by Healthcare Professionals: Reaction Characteristics and Time to Reporting. J. Clin. Pharmacol. 2018;58(10):1332–1339. DOI: 10.1002/jcph.1148Выхристенко Л.Р., Величинская О.Г., Сидоренко Е.В., Захарова О.В. Синдром Стивенса–Джонсона и токсический эпидермальный некролиз у пациентов Витебской областной клинической больницы: ретроспективный анализ. Иммунопатология, аллергология, инфектология. 2017;(4):21–30. DOI: 10.14427/jipai.2017.4.21Vykhrystsenko L, Velichansky O, Sidorenko E, Zakharova O. The Stevens–Johnson syndrome and toxic epidermal necrolysis in patients of Vitebsk regional clinical hospital: a retrospective analysis. Immunopathology, Allergology, Infectology. 2017;4:21–30. (in Russian) DOI: 10.14427/jipai.2017.4.21Niebel D., Wenzel J. Immunpathologie von kutanen Medikamentennebenwirkungen. Pathologe. 2018;39(6):563–570. DOI:10.1007/s00292-018-0487-xNiebel D., Wenzel J. Immunpathologie von kutanen Medikamentennebenwirkungen. Pathologe. 2018;39(6):563–570. DOI:10.1007/s00292-018-0487-xGraudins L, Trubiano J., Zubrinich C., Elliott A., Aung A. Medication-related anaphylaxis treated in hospital: Agents implicated, patient outcomes, and management lessons. Pharmacoepidemiol. Drug. Saf. 2018;27(9):1029–1033. DOI: 10.1002/pds.4587Graudins L, Trubiano J., Zubrinich C., Elliott A., Aung A. Medication-related anaphylaxis treated in hospital: Agents implicated, patient outcomes, and management lessons. Pharmacoepidemiol. Drug. Saf. 2018;27(9):1029–1033. DOI: 10.1002/pds.4587Kubanova A, Samtsov A, Zaslavsky D. The roots of international dermatology. Vestnik dermatologii i venerologii. 2011;87(3):162–173. DOI: 0.25208/vdv1049 (in Russian)Kubanova A, Samtsov A, Zaslavsky D. The roots of international dermatology. Vestnik dermatologii i venerologii. 2011;87(3):162–173. DOI: 0.25208/vdv1049 (in Russian)Toksidermiya. Klinicheskie rekomendatsii MZ RF. 2016. URL: http://kokb45.ru/wp-content/ uploads/2018/06/Toksidermiya.pdf (Accessed Dec 06, 2020). (in Russian)]Toksidermiya. Klinicheskie rekomendatsii MZ RF. 2016. URL: http://kokb45.ru/wp-content/ uploads/2018/06/Toksidermiya.pdf (Accessed Dec 06, 2020). (in Russian)Schneider J.A., Cohen P.R. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Adv. Ther. 2017;34(6):1235–1244. DOI: 10.1007/s12325-017-0530-ySchneider J.A., Cohen P.R. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Adv. Ther. 2017;34(6):1235–1244. DOI: 10.1007/s12325-017-0530-yDodiuk-Gad R.P., Chung W.H., Valeyrie-Allanore L., Shear N.H. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. Am. J. Clin. Dermatol. 2015;16(6):475–93. DOI: 10.1007/s40257-015-0158-0Dodiuk-Gad R.P., Chung W.H., Valeyrie-Allanore L., Shear N.H. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. Am. J. Clin. Dermatol. 2015;16(6):475–93. DOI: 10.1007/s40257-015-0158-0Letko E., Papaliodis D., Papaliodis G., Daoud Y., Ahmed A., Foster C. Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Annals of Allergy, Asthma & Immunology. 2005;94(4):419–436. DOI: 10.1016/s1081-1206(10)61112-xLetko E., Papaliodis D., Papaliodis G., Daoud Y., Ahmed A., Foster C. Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Annals of Allergy, Asthma & Immunology. 2005;94(4):419–436. DOI: 10.1016/s1081-1206(10)61112-xGoodman H. Nikolsky signpage from notable contributors to the knowledge of dermatology. AMA Arch. Derm. Syphilol. 1953;68(3):334. DOI: 10.1001/archderm.1953.01540090096013Goodman H. Nikolsky signpage from notable contributors to the knowledge of dermatology. AMA Arch. Derm. Syphilol. 1953;68(3):334. DOI: 10.1001/archderm.1953.01540090096013Harr T., French L.E. Toxic epidermal necrolysis and Stevens– Johnson syndrome. Orphanet J. Rare Dis. 2010;16(5):39. DOI: 10.1186/1750-1172-5-39Harr T., French L.E. Toxic epidermal necrolysis and Stevens– Johnson syndrome. Orphanet J. Rare Dis. 2010;16(5):39. DOI: 10.1186/1750-1172-5-39Shegaonkar S.H. Bilateral panophthalmitis following toxic epidermal necrolysis: A case report. Indian J. Ophthalmol. 2020;68(3):538– 540. DOI: 10.4103/ijo.IJO_1208_19Shegaonkar S.H. Bilateral panophthalmitis following toxic epidermal necrolysis: A case report. Indian J. Ophthalmol. 2020;68(3):538– 540. DOI: 10.4103/ijo.IJO_1208_19Hasegawa A., Abe R. Recent advances in managing and understanding Stevens–Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020;16(9):F1000 Faculty Rev-612. DOI: 10.12688/f1000research.24748.1Hasegawa A., Abe R. Recent advances in managing and understanding Stevens–Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020;16(9):F1000 Faculty Rev-612. DOI: 10.12688/f1000research.24748.1Jun I., Rim J.H., Kim M.K., Yoon K.C., Joo C.K., Kinoshita S., Seo K.Y., Ueta M. Association of human antigen class I genes with cold medicine-related Stevens–Johnson syndrome with severe ocular complications in a Korean population. Br. J. Ophthalmol. 2019;103(4):573–576. DOI: 10.1136/bjophthalmol-2018-313263Jun I., Rim J.H., Kim M.K., Yoon K.C., Joo C.K., Kinoshita S., Seo K.Y., Ueta M. Association of human antigen class I genes with cold medicine-related Stevens–Johnson syndrome with severe ocular complications in a Korean population. Br. J. Ophthalmol. 2019;103(4):573–576. DOI: 10.1136/bjophthalmol-2018-313263Nicoletti P., Barrett S., McEvoy L., Daly A.K., Aithal G., Lucena M.I., Andrade R.J., Wadelius M., Hallberg P., Stephens C., Bjornsson E.S., Friedmann P., Kainu K., Laitinen T., Marson A., Molokhia M., Phillips E., Pichler W., Romano A., Shear N., Sills G., Tanno L.K., Swale A., Floratos A., Shen Y., Nelson M.R., Watkins P.B., Daly M.J., Morris A.P., Alfirevic A., Pirmohamed M. Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. Clin Pharmacol. Ther. 2019;106(5):1028–1036. DOI: 10.1002/cpt.1493Nicoletti P., Barrett S., McEvoy L., Daly A.K., Aithal G., Lucena M.I., Andrade R.J., Wadelius M., Hallberg P., Stephens C., Bjornsson E.S., Friedmann P., Kainu K., Laitinen T., Marson A., Molokhia M., Phillips E., Pichler W., Romano A., Shear N., Sills G., Tanno L.K., Swale A., Floratos A., Shen Y., Nelson M.R., Watkins P.B., Daly M.J., Morris A.P., Alfirevic A., Pirmohamed M. Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. Clin Pharmacol. Ther. 2019;106(5):1028–1036. DOI: 10.1002/cpt.1493Ke C.H., Chung W.H., Wen Y.H., Huang Y.B., Chuang H.Y., Tain Y.L., Wang Y.L., Wu C.C., Hsu C.N. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions. J. Rheumatol. 2017;44(6):835– 843. DOI: 10.3899/jrheum.151476Ke C.H., Chung W.H., Wen Y.H., Huang Y.B., Chuang H.Y., Tain Y.L., Wang Y.L., Wu C.C., Hsu C.N. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions. J. Rheumatol. 2017;44(6):835– 843. DOI: 10.3899/jrheum.151476Jutkowitz E., Dubreuil M., Lu N., Kuntz K.M., Choi H.K. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum. 2017;46(5):594–600. DOI: 10.1016/j.semarthrit.2016.10.009Jutkowitz E., Dubreuil M., Lu N., Kuntz K.M., Choi H.K. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum. 2017;46(5):594–600. DOI: 10.1016/j.semarthrit.2016.10.009Correia O., Delgado L., Ramos J., Resende C., Torrinha J. Cutaneous T-CellRecruitmentinToxicEpidermalNecrolysis:FurtherEvidenceof CD8+ Lymphocyte Involvement. Arch. Dermatol. 1993;129(4):466– 468. DOI: 10.1001/archderm.1993.01680250078010Correia O., Delgado L., Ramos J., Resende C., Torrinha J. Cutaneous T-CellRecruitmentinToxicEpidermalNecrolysis:FurtherEvidenceof CD8+ Lymphocyte Involvement. Arch. Dermatol. 1993;129(4):466– 468. DOI: 10.1001/archderm.1993.01680250078010Paul C., Wolkenstein P., Adle H., Wechsler J., Garchon H.J., Revuz J., Roujeau J.C. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Brit. J. Dermatology. 1996;134(4):710– 714. DOI: 10.1111/j.1365-2133.1996.tb06976.xPaul C., Wolkenstein P., Adle H., Wechsler J., Garchon H.J., Revuz J., Roujeau J.C. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Brit. J. Dermatology. 1996;134(4):710– 714. DOI: 10.1111/j.1365-2133.1996.tb06976.xViard I., Wehrli P., Bullani R., Schneider P., Holler N., Salomon D., Hunziker T., Saurat J.H., Tschopp J., French L.E. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;16;282(5388):490–3. DOI: 10.1126/science.282.5388.490Viard I., Wehrli P., Bullani R., Schneider P., Holler N., Salomon D., Hunziker T., Saurat J.H., Tschopp J., French L.E. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;16;282(5388):490–3. DOI: 10.1126/science.282.5388.490Nassif A., Bensussan A., Boumsell L., Deniaud A., Moslehi H., Wolkenstein P., Bagot M., Roujeau J.C. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 2004;114(5):1209–15. DOI: 10.1016/j.jaci.2004.07.047Nassif A., Bensussan A., Boumsell L., Deniaud A., Moslehi H., Wolkenstein P., Bagot M., Roujeau J.C. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 2004;114(5):1209–15. DOI: 10.1016/j.jaci.2004.07.047Wei C., Chung W., Huang H., Chen Y., Hung S. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens–Johnson syndrome. J. Allergy Clin. Immunol. 2012;129(6):1562–1569.e5. DOI: 10.1016/j.jaci.2011.12.990Wei C., Chung W., Huang H., Chen Y., Hung S. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens–Johnson syndrome. J. Allergy Clin. Immunol. 2012;129(6):1562–1569.e5. DOI: 10.1016/j.jaci.2011.12.990Génin E, Schumacher M, Roujeau J., Naldi L., Liss Y., Kazma R., Sekula P., Hovnanian A., Mockenhaupt M. Genome-wide association study of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J. Rare Dis. 2011;6:52. DOI: 10.1186/1750-1172-6-52Génin E, Schumacher M, Roujeau J., Naldi L., Liss Y., Kazma R., Sekula P., Hovnanian A., Mockenhaupt M. Genome-wide association study of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J. Rare Dis. 2011;6:52. DOI: 10.1186/1750-1172-6-52Borchers A., Lee J., Naguwa S., Cheema G., Gershwin M. Stevens– Johnson syndrome and toxic epidermal necrolysis. Autoimmun. Rev. 2008;7(8):598–605. DOI: 10.1016/j.autrev.2008.06.004Borchers A., Lee J., Naguwa S., Cheema G., Gershwin M. Stevens– Johnson syndrome and toxic epidermal necrolysis. Autoimmun. Rev. 2008;7(8):598–605. DOI: 10.1016/j.autrev.2008.06.004Frey N., Jossi J., Bodmer M., Bircher A., Jick S.S., Meier C.R., Spoendlin J. The Epidemiology of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. J. Invest. Dermatol. 2017;137(6):1240–1247. DOI: 10.1016/j.jid.2017.01.031Frey N., Jossi J., Bodmer M., Bircher A., Jick S.S., Meier C.R., Spoendlin J. The Epidemiology of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. J. Invest. Dermatol. 2017;137(6):1240–1247. DOI: 10.1016/j.jid.2017.01.031Jang M.S., Lee J.Y., Kim J., Kim G.W., Kim B.K., Kim J.Y., Park H.W., Cho S.H., Min K.U., Kang H.R. Incidence of Stevens– Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea. PLoS One. 201611;11(11):e0165933. DOI: 10.1371/journal.pone.0165933Jang M.S., Lee J.Y., Kim J., Kim G.W., Kim B.K., Kim J.Y., Park H.W., Cho S.H., Min K.U., Kang H.R. Incidence of Stevens– Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea. PLoS One. 201611;11(11):e0165933. DOI: 10.1371/journal.pone.0165933Naegele D., Sekula P., Paulmann M., Mockenhaupt M. Incidence of Stevens–Johnson syndrom/toxic epidermal necrolysis: results of 10 years from the German registry. Pharmacoepidemiol. Drug. Saf. 2017;26:3Naegele D., Sekula P., Paulmann M., Mockenhaupt M. Incidence of Stevens–Johnson syndrom/toxic epidermal necrolysis: results of 10 years from the German registry. Pharmacoepidemiol. Drug. Saf. 2017;26:3Hsu D., Brieva J., Silverberg N., Silverberg J. Morbidity and Mortality of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. J. Invest. Dermatol. 2016;136(7):1387–1397. DOI: 10.1016/j.jid.2016.03.023Hsu D., Brieva J., Silverberg N., Silverberg J. Morbidity and Mortality of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. J. Invest. Dermatol. 2016;136(7):1387–1397. DOI: 10.1016/j.jid.2016.03.023Micheletti R.G., Chiesa-Fuxench Z., Noe M.H., Stephen S., Aleshin M., Agarwal A., Boggs J., Cardones A.R., Chen J.K., Cotliar J., Davis M.D.P., Dominguez A., Fox L.P., Gordon S., Hamrick R., Ho B., Hughey L.C., Jones L.M., Kaffenberger B.H., Kindley K., Kroshinsky D., Kwong B.Y., Miller D.D., Mostaghimi A., Musiek A., Ortega-Loayza A.G., Patel R., Posligua A., Rani M., Saluja S., Sharon V.R., Shinkai K., John J.S., Strickland N., Summers E.M., Sun N., Wanat K.A., Wetter D.A., Worswick S., Yang C., Margolis D.J., Gelfand J.M., Rosenbach M. Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. J. Invest. Dermatol. 2018;138(11):2315–2321. DOI: 10.1016/j.jid.2018.04.027Micheletti R.G., Chiesa-Fuxench Z., Noe M.H., Stephen S., Aleshin M., Agarwal A., Boggs J., Cardones A.R., Chen J.K., Cotliar J., Davis M.D.P., Dominguez A., Fox L.P., Gordon S., Hamrick R., Ho B., Hughey L.C., Jones L.M., Kaffenberger B.H., Kindley K., Kroshinsky D., Kwong B.Y., Miller D.D., Mostaghimi A., Musiek A., Ortega-Loayza A.G., Patel R., Posligua A., Rani M., Saluja S., Sharon V.R., Shinkai K., John J.S., Strickland N., Summers E.M., Sun N., Wanat K.A., Wetter D.A., Worswick S., Yang C., Margolis D.J., Gelfand J.M., Rosenbach M. Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. J. Invest. Dermatol. 2018;138(11):2315–2321. DOI: 10.1016/j.jid.2018.04.027Теплюк Н.П., Кадырова З.С. Разнообразие клинических проявлений лекарственной токсидермии у больных, находившихся в клинике кожных и венерических болезней им. В.А. Рахманова ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России. Современные проблемы науки и образования. 2019;3. DOI: 10.17513/spno.28900Teplyuk N.P., Kadyrova Z.S. Diversity of clinical manifestations of drug toxidermia in patients who were in the clinic of skin and sexually transmitted diseases named after V.A. Rakhmanova FGAOU at the First Moscow State Medical University named after I.M. Sechenov Ministry of Health of Russia. Modern problems of science and education. 2019;3. (in Russian). DOI: 10.17513/spno.28900Sekula P., Dunant A., Mockenhaupt M., Naldi L., Bouwes Bavinck J.N., Halevy S., Kardaun S., Sidoroff A., Liss Y., Schumacher M., Roujeau J.C. RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. J. Invest. Dermatol. 2013;133(5):1197–204. DOI: 10.1038/jid.2012.510Sekula P., Dunant A., Mockenhaupt M., Naldi L., Bouwes Bavinck J.N., Halevy S., Kardaun S., Sidoroff A., Liss Y., Schumacher M., Roujeau J.C. RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. J. Invest. Dermatol. 2013;133(5):1197–204. DOI: 10.1038/jid.2012.510Синдром Стивенса–Джонсона. Клинические рекомендации МЗ РФ. 2016. URL: https://www.cnikvi.ru/docs/clinic_recs/klinicheskie-rekomendatsii-2017/Синдром%20Стивенса-Джонсона.КР228.docx (дата доступа 30.03.2020).Sindrom Stivensa–Dzhonsona. Klinicheskie rekomendatsii MZ RF. 2016. URL: https://www.cnikvi.ru/docs/clinic_recs/klinicheskie-rekomendatsii-2017/Синдром%20Стивенса–Джонсона.КР228.docx (Accessed March 30, 2020). (in Russian)Abe R., Yoshioka N., Murata J., Fujita Y, Shimizu H. Granulysin as a marker for early diagnosis of the Stevens–Johnson syndrome. Ann. Intern. Med. 2009;151(7):514–515. DOI: 10.7326/0003-4819-151-7-200910060-00016Abe R., Yoshioka N., Murata J., Fujita Y, Shimizu H. Granulysin as a marker for early diagnosis of the Stevens–Johnson syndrome. Ann. Intern. Med. 2009;151(7):514–515. DOI: 10.7326/0003-4819-151-7-200910060-00016Hasegawa A., Shinkuma S., Hayashi R., Hama N., Watanabe H., Kinoshita M., Ogawa Y., Abe R. RIP3 as a diagnostic and severity marker for Stevens–Johnson syndrome and toxic epidermal necrolysis. J. Allergy Clin. Immunol. Pract. 2020;8(5):1768–1771.e7. DOI: 10.1016/j.jaip.2020.01.006Hasegawa A., Shinkuma S., Hayashi R., Hama N., Watanabe H., Kinoshita M., Ogawa Y., Abe R. RIP3 as a diagnostic and severity marker for Stevens–Johnson syndrome and toxic epidermal necrolysis. J. Allergy Clin. Immunol. Pract. 2020;8(5):1768–1771.e7. DOI: 10.1016/j.jaip.2020.01.006Таирова Р.Т., Гайдина Т.А., Дворников А.С., Тазартукова А.Д., Лянг О.В. Сложности дифференциальной диагностики кожных проявлений при коронавирусной инфекции. Вестник РГМУ. 2020;(5):109–115. DOI: 10.24075/brsmu.2020.062Tairova R.T., Gaydina T.A., Dvornikov A.S., Tazartukova A.D., Lyang O.V. Difficulties in differential diagnosis of cutaneous manifestations in patients with coronavirus infection. Bulletin of RSMU. 2020;(5):102–107. (in Russian). DOI: 10.24075/brsmu.2020.062Zimmermann S., Sekula P., Venhoff M., Motschall E., Knaus J., Schumacher M., Mockenhaupt M. Systemic Immunomodulating Therapies for Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis:ASystematic Review and Meta-analysis. JAMA Dermatol. 2017;153(6):514–522. DOI: 10.1001/jamadermatol.2016.5668Zimmermann S., Sekula P., Venhoff M., Motschall E., Knaus J., Schumacher M., Mockenhaupt M. Systemic Immunomodulating Therapies for Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis:ASystematic Review and Meta-analysis. JAMA Dermatol. 2017;153(6):514–522. DOI: 10.1001/jamadermatol.2016.5668Terblanche A., Meyer J., Godman B., Summers R. Impact of a pharmacistdriven pharmacovigilance system in a secondary hospital in the Gauteng Province of South Africa. Hosp. Pract. 2018;46(4):221–228. DOI: 10.1080/21548331.2018.1510708Terblanche A., Meyer J., Godman B., Summers R. Impact of a pharmacistdriven pharmacovigilance system in a secondary hospital in the Gauteng Province of South Africa. Hosp. Pract. 2018;46(4):221–228. DOI: 10.1080/21548331.2018.1510708Schmiedl S., Rottenkolber M., Szymanski J., Drewelow B., Siegmund W., Hippius M., Farker K., Guenther I.R., Hasford J., Thuermann P.A. German Net of Regional Pharmacovigilance Centers (NRPC). Preventable ADRs leading to hospitalization -results of a long-term prospective safety study with 6,427 ADR cases focusing on elderly patients. Expert Opin. Drug. Saf. 2018;17(2):125–137. DOI: 10.1080/14740338.2018.1415322Schmiedl S., Rottenkolber M., Szymanski J., Drewelow B., Siegmund W., Hippius M., Farker K., Guenther I.R., Hasford J., Thuermann P.A. German Net of Regional Pharmacovigilance Centers (NRPC). Preventable ADRs leading to hospitalization -results of a long-term prospective safety study with 6,427 ADR cases focusing on elderly patients. Expert Opin. Drug. Saf. 2018;17(2):125–137. DOI: 10.1080/14740338.2018.1415322The Canadian Deprescribing Network. URL: https://www.deprescribingnetwork.ca/canadian-deprescribing-network (Accessed March 30, 2020)The Canadian Deprescribing Network. URL: https://www.deprescribingnetwork.ca/canadian-deprescribing-network (Accessed March 30, 2020)

The authors declare that there are no conflicts of interest present.